Search

Your search keyword '"KABBINAVAR, FAIROOZ F."' showing total 287 results
Start Over Author "KABBINAVAR, FAIROOZ F."
287 results on '"KABBINAVAR, FAIROOZ F."'

1. Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database

Author

Margalit, Ofer, Harmsen, William S., Shacham-Shmueli, Einat, Voss, Molly M., Boursi, Ben, Wagner, Anna D., Cohen, Romain, Olswold, Curtis L., Saltz, Leonard B., Goldstein, Daniel A., Hurwitz, Herbert, Tebbutt, Niall C., Kabbinavar, Fairooz F., Adams, Richard A., Chibaudel, Benoist, Grothey, Axel, Yoshino, Takayuki, Zalcberg, John, de Gramont, Aimery, Shi, Qian, and Lenz, Heinz-Josef

Published
2022
Full Text
View/download PDF

2. Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

Author

Sjoquist, Katrin M, Renfro, Lindsay A, Simes, R John, Tebbutt, Niall C, Clarke, Stephen, Seymour, Matthew T, Adams, Richard, Maughan, Timothy S, Saltz, Leonard, Goldberg, Richard M, Schmoll, Hans-Joachim, Van Cutsem, Eric, Douillard, Jean-Yves, Hoff, Paulo M, Hecht, Joel Randolph, Tournigand, Christophe, Punt, Cornelis JA, Koopman, Miriam, Hurwitz, Herbert, Heinemann, Volker, Falcone, Alfredo, Porschen, Rainer, Fuchs, Charles, Diaz-Rubio, Eduardo, Aranda, Enrique, Bokemeyer, Carsten, Souglakos, Ioannis, Kabbinavar, Fairooz F, Chibaudel, Benoist, Meyers, Jeffrey P, Sargent, Daniel J, de Gramont, Aimery, and Zalcberg, John R

Subjects
Patient Safety, Colo-Rectal Cancer, Digestive Diseases, Prevention, Clinical Research, Cancer, Aged, Colorectal Neoplasms, Disease Progression, Female, Humans, Male, Middle Aged, Neoadjuvant Therapy, Neoplasm Metastasis, Nomograms, Precision Medicine, Prognosis, Progression-Free Survival, Survival Analysis, Fondation Aide et Recherche en Cancerologie Digestive Group, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundEstimating prognosis on the basis of clinicopathologic factors can inform clinical practice and improve risk stratification for clinical trials. We constructed prognostic nomograms for one-year overall survival and six-month progression-free survival in metastatic colorectal carcinoma by using the ARCAD database.MethodsData from 22 674 patients in 26 randomized phase III clinical trials since 1997 were used to construct and validate Cox models, stratified by treatment arm within each study. Candidate variables included baseline age, sex, body mass index, performance status, colon vs rectal cancer, prior chemotherapy, number and location of metastatic sites, tumor mutation status (BRAF, KRAS), bilirubin, albumin, white blood cell count, hemoglobin, platelets, absolute neutrophil count, and derived neutrophil-to-lymphocyte ratio. Missing data (50% vs 50% vs

Published
2018

6. The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma

Author

McDermott, David F, Cheng, Su-Chun, Signoretti, Sabina, Margolin, Kim A, Clark, Joseph I, Sosman, Jeffrey A, Dutcher, Janice P, Logan, Theodore F, Curti, Brendan D, Ernstoff, Marc S, Appleman, Leonard, Wong, Michael KK, Khushalani, Nikhil I, Oleksowicz, Leslie, Vaishampayan, Ulka N, Mier, James W, Panka, David J, Bhatt, Rupal S, Bailey, Alexandra S, Leibovich, Bradley C, Kwon, Eugene D, Kabbinavar, Fairooz F, Belldegrun, Arie S, Figlin, Robert A, Pantuck, Allan J, Regan, Meredith M, and Atkins, Michael B

Subjects
Cancer, Kidney Disease, Rare Diseases, Clinical Research, Prevention, Adult, Aged, Antineoplastic Agents, Carcinoma, Renal Cell, Humans, Interleukin-2, Kidney Neoplasms, Middle Aged, Neoplasm Metastasis, Prognosis, Recombinant Proteins, Risk Factors, Treatment Outcome, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeHigh-dose aldesleukin (HD IL2) received FDA approval for the treatment of metastatic renal cell carcinoma (MRCC) in 1992, producing a 14% objective response rate (ORR) and durable remissions. Retrospective studies suggested that clinical and pathologic features could predict for benefit. The Cytokine Working Group conducted this prospective trial to validate proposed predictive markers of response to HD IL2.Experimental designStandard HD IL2 was administered to prospectively evaluate whether the ORR of patients with mRCC with "good" predictive pathologic features based on an "integrated selection" model [ISM (e.g., clear-cell histology subclassification and carbonic anhydrase-9 (CA-9) IHC staining] was significantly higher than the ORR of a historical, unselected population. Archived tumor was collected for pathologic analysis including tumor programmed death-ligand 1 (PD-L1) expression.ResultsOne hundred and twenty eligible patients were enrolled between June 11 and September 7; 70% were Memorial Sloan Kettering Cancer Center (New York, NY) intermediate risk, 96% had clear cell RCC, and 99% had prior nephrectomy. The independently assessed ORR was 25% (30/120, 95% CI, 17.5%-33.7%, P = 0.0014; 3 complete responses, 27 partial responses) and was higher than a historical ORR. Thirteen patients (11%) remained progression free at 3 years and the median overall survival was 42.8 months. ORR was not statistically different by ISM classification ("good-risk" 23% vs. "poor-risk" 30%; P = 0.39). ORR was positively associated with tumor PD-L1 expression (P = 0.01) by IHC.ConclusionsIn this prospective, biomarker validation study, HD IL2 produced durable remissions and prolonged survival in both "good" and "poor-risk" patients. The proposed ISM was unable to improve the selection criteria. Novel markers (e.g., tumor PD L1 expression) appeared useful, but require independent validation.

Published
2015

7. Individual Patient Data Analysis of Progression-Free Survival Versus Overall Survival As a First-Line End Point for Metastatic Colorectal Cancer in Modern Randomized Trials: Findings From the Analysis and Research in Cancers of the Digestive System Database

Author

Shi, Qian, de Gramont, Aimery, Grothey, Axel, Zalcberg, John, Chibaudel, Benoist, Schmoll, Hans-Joachim, Seymour, Matthew T, Adams, Richard, Saltz, Leonard, Goldberg, Richard M, Punt, Cornelis JA, Douillard, Jean-Yves, Hoff, Paulo M, Hecht, Joel Randolph, Hurwitz, Herbert, Díaz-Rubio, Eduardo, Porschen, Rainer, Tebbutt, Niall C, Fuchs, Charles, Souglakos, John, Falcone, Alfredo, Tournigand, Christophe, Kabbinavar, Fairooz F, Heinemann, Volker, Van Cutsem, Eric, Bokemeyer, Carsten, Buyse, Marc, and Sargent, Daniel J

Subjects
Clinical Trials and Supportive Activities, Digestive Diseases, Clinical Research, Cancer, Colo-Rectal Cancer, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors, Antineoplastic Agents, Biomedical Research, Colorectal Neoplasms, Databases, Factual, Digestive System, Disease-Free Survival, ErbB Receptors, Humans, Middle Aged, Neoplasm Metastasis, Neoplasms, Outcome Assessment, Health Care, Prognosis, Protein Kinase Inhibitors, Randomized Controlled Trials as Topic, Young Adult, Clinical Sciences, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

PurposeProgression-free survival (PFS) has previously been established as a surrogate for overall survival (OS) for first-line metastatic colorectal cancer (mCRC). Because mCRC treatment has advanced in the last decade with extended OS, this surrogacy requires re-examination.MethodsIndividual patient data from 16,762 patients were available from 22 first-line mCRC studies conducted from 1997 to 2006; 12 of those studies tested antiangiogenic and/or anti-epidermal growth factor receptor agents. The relationship between PFS (first event of progression or death) and OS was evaluated by using R(2) statistics (the closer the value is to 1, the stronger the correlation) from weighted least squares regression of trial-specific hazard ratios estimated by using Cox and Copula models.ResultsForty-four percent of patients received a regimen that included biologic agents. Median first-line PFS was 8.3 months, and median OS was 18.2 months. The correlation between PFS and OS was modest (R(2), 0.45 to 0.69). Analyses limited to trials that tested treatments with biologic agents, nonstrategy trials, or superiority trials did not improve surrogacy.ConclusionIn modern mCRC trials, in which survival after the first progression exceeds time to first progression, a positive but modest correlation was observed between OS and PFS at both the patient and trial levels. This finding demonstrates the substantial variability in OS introduced by the number of lines of therapy and types of effective subsequent treatments and the associated challenge to the use of OS as an end point to assess the benefit attributable to a single line of therapy. PFS remains an appropriate primary end point for first-line mCRC trials to detect the direct treatment effect of new agents.

Published
2015

8. Corrigendum to "Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3369 patients in the ARCAD database" Eur J Cancer. 2023 Jan;178:162–170

Author

Margalit, Ofer, primary, Harmsen, William S., additional, Shacham-Shmueli, Einat, additional, Voss, Molly M., additional, Boursi, Ben, additional, Wagner, Anna D., additional, Cohen, Romain, additional, Olswold, Curtis L., additional, Saltz, Leonard B., additional, Goldstein, Daniel A., additional, Hurwitz, Herbert, additional, Tebbutt, Niall C., additional, Kabbinavar, Fairooz F., additional, Adams, Richard A., additional, Chibaudel, Benoist, additional, Grothey, Axel, additional, Yoshino, Takayuki, additional, Zalcberg, John, additional, de Gramont, Aimery, additional, Shi, Qian, additional, and Lenz, Heinz-Josef, additional

Published
2023
Full Text
View/download PDF

9. Effect of bevacizumab in older patients with metastatic colorectal cancer: pooled analysis of four randomized studies

Author

Cassidy, James, Saltz, Leonard B., Giantonio, Bruce J., Kabbinavar, Fairooz F., Hurwitz, Herbert I., and Rohr, Ulrich-Peter

Subjects
Medicine & Public Health, Hematology, Internal Medicine, Cancer Research, Oncology, Bevacizumab, Chemotherapy, Metastatic colorectal cancer, Older patients, Pooled analysis
Abstract

Bevacizumab is frequently combined with 5-fluorouracil-based chemotherapy for patients with metastatic colorectal cancer (mCRC). The relative benefit of bevacizumab in older patients has not been widely studied and is of interest.This retrospective analysis used data from three first-line randomized controlled studies and one second-line randomized controlled study of bevacizumab plus chemotherapy in medically fit (Eastern Cooperative Oncology Group performance status 0 or 1) patients with mCRC. Overall survival (OS) and on-treatment progression-free survival (PFS) were assessed in patients aged

Published
2010

10. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database

Author

Ou, Fang-Shu, primary, Ahn, Daniel H., additional, Dixon, Jesse G., additional, Grothey, Axel, additional, Lou, Yiyue, additional, Kasi, Pashtoon M., additional, Hubbard, Joleen M., additional, Van Cutsem, Eric, additional, Saltz, Leonard B., additional, Schmoll, Hans-Joachim, additional, Goldberg, Richard M., additional, Venook, Alan P., additional, Hoff, Paulo, additional, Douillard, Jean-Yves, additional, Hecht, J. Randolph, additional, Hurwitz, Herbert, additional, Punt, Cornelis J. A., additional, Koopman, Miriam, additional, Bokemeyer, Carsten, additional, Fuchs, Charles S., additional, Diaz-Rubio, Eduardo, additional, Tebbutt, Niall C., additional, Cremolini, Chiara, additional, Kabbinavar, Fairooz F., additional, Bekaii-Saab, Tanios, additional, Chibaudel, Benoist, additional, Yoshino, Takayuki, additional, Zalcberg, John, additional, Adams, Richard A., additional, de Gramont, Aimery, additional, and Shi, Qian, additional

Published
2023
Full Text
View/download PDF

11. Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database

Author

Cancer, Epi Kanker Team B, MS Medische Oncologie, Ou, Fang Shu, Ahn, Daniel H., Dixon, Jesse G., Grothey, Axel, Lou, Yiyue, Kasi, Pashtoon M., Hubbard, Joleen M., Van Cutsem, Eric, Saltz, Leonard B., Schmoll, Hans Joachim, Goldberg, Richard M., Venook, Alan P., Hoff, Paulo, Douillard, Jean Yves, Hecht, J. Randolph, Hurwitz, Herbert, Punt, Cornelis J.A., Koopman, Miriam, Bokemeyer, Carsten, Fuchs, Charles S., Diaz-Rubio, Eduardo, Tebbutt, Niall C., Cremolini, Chiara, Kabbinavar, Fairooz F., Bekaii-Saab, Tanios, Chibaudel, Benoist, Yoshino, Takayuki, Zalcberg, John, Adams, Richard A., de Gramont, Aimery, Shi, Qian, Cancer, Epi Kanker Team B, MS Medische Oncologie, Ou, Fang Shu, Ahn, Daniel H., Dixon, Jesse G., Grothey, Axel, Lou, Yiyue, Kasi, Pashtoon M., Hubbard, Joleen M., Van Cutsem, Eric, Saltz, Leonard B., Schmoll, Hans Joachim, Goldberg, Richard M., Venook, Alan P., Hoff, Paulo, Douillard, Jean Yves, Hecht, J. Randolph, Hurwitz, Herbert, Punt, Cornelis J.A., Koopman, Miriam, Bokemeyer, Carsten, Fuchs, Charles S., Diaz-Rubio, Eduardo, Tebbutt, Niall C., Cremolini, Chiara, Kabbinavar, Fairooz F., Bekaii-Saab, Tanios, Chibaudel, Benoist, Yoshino, Takayuki, Zalcberg, John, Adams, Richard A., de Gramont, Aimery, and Shi, Qian

Published
2023

13. Bevacizumab in first-line therapy in lung metastases of colorectal cancer: An ARCAD pooled analysis.

Author

Shmueli, Einat S, primary, Raeisi, Morteza, additional, Chibaudel, Benoist, additional, Hurwitz, Herbert, additional, Saltz, Leonard B., additional, Kabbinavar, Fairooz F., additional, Tebbutt, Niall C., additional, Grothey, Axel, additional, Adams, Richard, additional, Zalcberg, John Raymond, additional, Yoshino, Takayuki, additional, Bachet, Jean-Baptiste, additional, Cohen, Romain, additional, Sharara, Lama, additional, Andre, Thierry, additional, Shi, Qian, additional, and De Gramont, Aimery, additional

Published
2023
Full Text
View/download PDF

14. Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database

Author

Margalit, Ofer, primary, Harmsen, William S., additional, Shacham-Shmueli, Einat, additional, Voss, Molly M., additional, Boursi, Ben, additional, Wagner, Anna D., additional, Cohen, Romain, additional, Olswold, Curtis L., additional, Saltz, Leonard B., additional, Goldstein, Daniel A., additional, Hurwitz, Herbert, additional, Tebbutt, Niall C., additional, Kabbinavar, Fairooz F., additional, Adams, Richard A., additional, Chibaudel, Benoist, additional, Grothey, Axel, additional, Yoshino, Takayuki, additional, Zalcberg, John, additional, de Gramont, Aimery, additional, Shi, Qian, additional, and Lenz, Heinz-Josef, additional

Published
2023
Full Text
View/download PDF

18. Trajectories of body weight change and survival among mCRC patients treated with systemic therapy: Pooled analysis from the ARCAD database.

Author

Franko, Jan, primary, Yin, Jun, additional, Adams, Richard, additional, Zalcberg, John Raymond, additional, Fiskum, Jack, additional, VanCutsem, Eric, additional, Goldberg, Richard M., additional, Hurwitz, Herbert I., additional, Bokemeyer, Carsten, additional, Kabbinavar, Fairooz F., additional, Curtis, Alexandra, additional, Chibaudel, Benoist, additional, Yoshino, Takayuki, additional, De Gramont, Aimery, additional, and Shi, Qian, additional

Published
2022
Full Text
View/download PDF

24. Prognostic Impact of Tumor Size on pT2 Renal Cell Carcinoma: An International Multicenter Experience

Author

Klatte, Tobias, Patard, Jean-Jacques, Goel, Rakhee H., Kleid, Mark D., Guille, Francois, Lobel, Bernard, Abbou, Clement-Claude, De La Taille, Alexandre, Tostain, Jacques, Cindolo, Luca, Altieri, Vincenzo, Ficarra, Vincenzo, Artibani, Walter, Prayer-Galetti, Tommaso, Allhoff, Ernst Peter, Schips, Luigi, Zigeuner, Richard, Figlin, Robert A., Kabbinavar, Fairooz F., Pantuck, Allan J., Belldegrun, Arie S., and Lam, John S.

Published
2007
Full Text
View/download PDF

25. Metachronous Bilateral Renal Cell Carcinoma: Risk Assessment, Prognosis and Relevance of the Primary-Free Interval

Author

Klatte, Tobias, Patard, Jean-Jacques, Wunderlich, Heiko, Goel, Rakhee H., Lam, John S., Junker, Kerstin, Schubert, Jörg, Böhm, Malte, Allhoff, Ernst P., Kabbinavar, Fairooz F., Crepel, Maxime, Cindolo, Luca, De La Taille, Alexandre, Tostain, Jacques, Mejean, Arnaud, Soulie, Michel, Bellec, Laurent, Bernhard, Jean Christophe, Ferriere, Jean-Marie, Pfister, Christian, Albouy, Baptiste, Colombel, Marc, Zisman, Amnon, Belldegrun, Arie S., and Pantuck, Allan J.

Published
2007
Full Text
View/download PDF

41. Evaluation of Continuous Tumor-Size-Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer

Author

Burzykowski, Tomasz, Coart, Elisabeth, Saad, Everardo D., Shi, Qian, Sommeijer, Dirkje W., Bokemeyer, Carsten, Diaz-Rubio, Eduardo, Douillard, Jean-Yves, Falcone, Alfredo, Fuchs, Charles S., Goldberg, Richard M., Hecht, J. Randolph, Hoff, Paulo M., Hurwitz, Herbert, Kabbinavar, Fairooz F., Koopman, Miriam, Maughan, Timothy S., Punt, Cornelis J. A., Saltz, Leonard, Schmoll, Hans-Joachim, Seymour, Matthew T., Tebbutt, Niall C., Tournigand, Christophe, Van Cutsem, Eric, de Gramont, Aimery, Zalcberg, John R., Buyse, Marc, Adam, Rene, Adams, Richard, Ajani, Jaffer, Allegra, Carmen Joseph, Andre, Thierry, Arnold, Dirk, Bachet, Jean-Baptiste, Benson, Al Bowen, Berlin, Jordan, Bleiberg, Harry, Bodoky, Gyorgy, Chibaudel, Benoist, Ellis, Lee, Eng, Cathy, Franko, Jan, Fujii, Masashi, Giantonio, Bruce J., Grothey, Axel, Haller, Daniel, Hamilton, Stan R., Hausner, Petr F., Heinemann, Volker, Herrera, Alain, Hochster, Howard S., Jonker, Derek J., Kaplan, Rick, Koeberle, Dieter, Kopetz, Scott, Labianca, Roberto F., Larsen, Annette K., Lenz, Heinz-Joseph, Lieu, Christopher, Louvet, Christophe, Loupakis, Fotios, Marshall, John, Mayer, Robert J., Meropol, Neal J., Mitchell, Edith P., O'Connell, Michael J., Peeters, Marc, Porschen, Rainer, Price, Timothy, Salem, Mohamed E., Schilsky, Richard, Shmueli, Einat Shacham, Sobrero, Alberto, Souglakos, John, Tabernero, Josep, Taieb, Julien, Tejpar, Sabine, Tempero, Margaret, Tsuji, Yasushi, Venook, Alan P., Yoshino, Takayuki, Weinberg, Benjamin A., Wolmark, Norman, Aide Rech Cancerologie Digestive, BURZYKOWSKI, Tomasz, Coart, E., Saad, E.D., Shi, Q., Sommeijer, D.W., Bokemeyer, C., Díaz-Rubio, E., Douillard, Jean-Yves, Falcone, A., Fuchs, C., Goldberg, R.M., Hecht, R., Hoff, P.M., Hurwitz, H., Kabbinavar, F.F., Koopman, M., Maughan, T., Punt, C.J.A., Saltz, L., Schmoll, Hans-Joachim, Seymour, M.T., Tebbutt, N.C., Tournigand, C., Van Cutsem, E., de Gramont, A., Zalcberg, J.R., BUYSE, Marc, Tejpar, S, Oncology, and CCA - Cancer Treatment and Quality of Life

Subjects
Oncology, medicine.medical_specialty, Bevacizumab, Endpoint Determination, Disease-Free Survival, Predictive Value of Tests, Internal medicine, Journal Article, medicine, Humans, Aide et Recherche en Cancerologie Digestive Group, Progression-free survival, Original Investigation, Randomized Controlled Trials as Topic, Medicine(all), Surrogate endpoint, business.industry, Research, Hazard ratio, Combination chemotherapy, General Medicine, Chemotherapy regimen, Online Only, Predictive value of tests, Human medicine, Colorectal Neoplasms, business, Biomarkers, Nadir (topography), medicine.drug
Abstract

Key Points Question Can end points based on the kinetics of tumor size after treatment be used as surrogates for overall survival in metastatic colorectal cancer? Findings In this pooled analysis of data from 20 randomized clinical trials, time to nadir and depth of nadir were modeled and assessed as potential surrogates for overall survival at the patient and trial levels. The associations found were weak or moderate; there were notable differences in tumor-size kinetics between antiangiogenic agents and anti–epidermal growth factor receptor agents. Meaning The implications of these results for early drug development and clinical practice are unclear and warrant further studies; the findings of this study reinforce the need to develop more reliable end points that reflect tumor biology and patient benefit., Importance Tumor measurements can be used to estimate time to nadir and depth of nadir as potential surrogates for overall survival (OS). Objective To assess time to nadir and depth of nadir as surrogates for OS in metastatic colorectal cancer. Design, Setting, and Participants Pooled analysis of 20 randomized clinical trials within the Aide et Recherche en Cancerologie Digestive database, which contains academic and industry-sponsored trials, was conducted. Three sets of comparisons were performed: chemotherapy alone, antiangiogenic agents, and anti–epidermal growth factor receptor agents in first-line treatment for patients with metastatic colorectal cancer. Main Outcomes and Measures Surrogacy of time to nadir and depth of nadir was assessed at the trial level based on joint modeling of relative tumor-size change vs baseline and OS. Treatment effects on time to nadir and on depth of nadir were defined in terms of between-arm differences in time to nadir and in depth of nadir, and both were assessed in linear regressions for their correlation with treatment effects (hazard ratios) on OS within each set. The strengths of association were quantified using sample-size–weighted coefficients of determination (R2), with values closer to 1.00 indicating stronger association. At the patient level, the correlation was assessed between modeled relative tumor-size change and OS. Results For 14 chemotherapy comparisons in 4289 patients, the R2 value was 0.63 (95% CI, 0.30-0.96) for the association between treatment effects on time to nadir and OS and 0.08 (95% CI, 0-0.37) for depth of nadir and OS. For 11 antiangiogenic agent comparisons (4854 patients), corresponding values of R2 were 0.25 (95% CI, 0-0.72) and 0.06 (95% CI, 0-0.35). For 8 anti–epidermal growth factor receptor comparisons (2684 patients), corresponding values of R2 were 0.24 (95% CI, 0-0.83) and 0.21 (95% CI, 0-0.78). Conclusions and Relevance In contrast with early reports favoring depth of response as a surrogate, these results suggest that neither time to nadir nor depth of nadir is an acceptable surrogate for OS in the first-line treatment of metastatic colorectal cancer., This study examines the use of time to nadir and depth of nadir as surrogate end points for overall survival in phase 3 randomized clinical trials evaluating first-line treatment in patients with metastatic colorectal cancer.

Published
2019

44. Clinicopathological features and prognosis of synchronous bilateral renal cell carcinoma: an international multicentre experience

Author

Klatte, Tobias, Wunderlich, Heiko, Patard, Jean-Jacques, Kleid, Mark D., Lam, John S., Junker, Kerstin, Schubert, Jörg, Böhm, Malte, Allhoff, Ernst P., Kabbinavar, Fairooz F., Crepel, Maxime, Cindolo, Luca, De La Taille, Alexandre, Tostain, Jacques, Mejean, Arnaud, Soulie, Michel, Bellec, Laurent, Bernhard, Jean Christophe, Ferriere, Jean-Marie, Pfister, Christian, Albouy, Baptiste, Colombel, Marc, Zisman, Amnon, Belldegrun, Arie S., and Pantuck, Allan J.

Published
2007

50. Evaluating gender as a predictive marker for response to bevacizuamb (Bev) in metastatic colorectal carcinoma (mCRC): Pooled analysis of 3369 patients (pts) in the ARCAD database.

Author

Margalit, Ofer, primary, Harmsen, William S., additional, shacham-Shmueli, Einat, additional, Petersen, Molly, additional, Boursi, Ben, additional, Saltz, Leonard B., additional, Adams, Richard, additional, Maughan, Tim, additional, Douillard, Jean-Yves, additional, Van Cutsem, Eric, additional, Hurwitz, Herbert, additional, Bokemeyer, Carsten, additional, Tebbutt, Niall C., additional, Kabbinavar, Fairooz F., additional, De Gramont, Aimery, additional, Shi, Qian, additional, and Lenz, Heinz-Josef, additional

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results